Elevance Health, Inc.
Elevance Health provides health insurance and healthcare services to individuals, employers, and government program members. Its Health Benefits segment offers risk-based health plans and administrative services, along with Medicare, Medicaid, commercial, federal employee, dental, vision, stop loss, and supplemental health products. The CarelonRx segment provides pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, and infusion services. Carelon Services offers physical, behavioral, pharmacy, and social-care capabilities, including care management, virtual and in-home care, payment integrity, analytics, and clinical data exchange. Elevance Health earns money from health plan premiums, administrative fees charged to self-funded employers, and pharmacy and health service fees through its Carelon businesses. Its brands include Anthem Blue Cross and Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon. The company is headquartered in Indianapolis, Indiana.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Elevance Health's EVP & Chief Digital Info Ofr, Lavu Ratnakar, sold 1,300 shares at $440 each, totaling $572,000. Ratnakar now directly owns 14,849 shares, according to an SEC filing.
LAVU RATNAKAR (EVP & Chief Digital Info Ofr) sold 1,300 shares of Elevance Health, Inc. (ELV) at $440.00 ($0.57M total) on 2026-11-05.
Elevance Health (NYSE: ELV) sued The Perfect Child ABA and its founder, alleging $800M in fraudulent billing since 2021. The suit claims deceptive practices, inflated prices, and threats to patients' families. Elevance Health paid $160M to The Perfect Child ABA. The company is also facing a federal lawsuit by a parent for $363,816.17 in alleged surprise billing.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ELV (Elevance Health, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 1 bearish.
Recent ELV coverage spans market movers, financial news and insider activity.
In the last 30 days, ELV insiders filed 14 SEC Form 4 transactions — no purchases and 14 sales ($5.2M). The most active reporter was Kaye Mark, EVP & CFO, with 13 filings.
Small insider sell may create modest downward pressure.
The insider sale may signal personal confidence level and could exert modest selling pressure.
The lawsuit exposes significant fraud risk and potential financial loss for Elevance Health.
Election-driven expectations are providing a tailwind to insurers.
Elevance may see modest gains from a friendlier policy environment.
AlphAI scores every news story that mentions ELV with an AI model for sentiment and relevance, and aggregates insider trades from Elevance Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elevance Health's EVP & Chief Digital Info Ofr, Lavu Ratnakar, sold 1,300 shares at $440 each, totaling $572,000. Ratnakar now directly owns 14,849 shares, according to an SEC filing.
LAVU RATNAKAR (EVP & Chief Digital Info Ofr) sold 1,300 shares of Elevance Health, Inc. (ELV) at $440.00 ($0.57M total) on 2026-11-05.
Elevance Health (NYSE: ELV) sued The Perfect Child ABA and its founder, alleging $800M in fraudulent billing since 2021. The suit claims deceptive practices, inflated prices, and threats to patients' families. Elevance Health paid $160M to The Perfect Child ABA. The company is also facing a federal lawsuit by a parent for $363,816.17 in alleged surprise billing.
U.S. election results drove sector-specific stock movements. Clean energy and healthcare stocks rose, while defense, data center, and some tech stocks fell. Key movers include NextEra Energy (+4%), Molina Healthcare (+8%), Lockheed Martin (-7%), CoreWeave (-9%), and Apple (+6%).
Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.
Bernstein predicts policy relief for health insurers and hospitals due to Democratic wins, citing potential delays in Medicaid cuts and restored subsidies. Centene, Molina, Elevance, and HCA Healthcare saw premarket gains. Bernstein expects Medicaid expansion in states like Texas and Georgia, benefiting insurers and hospitals.
Morningstar upgraded 24 US-listed stocks to 4 stars, including HSBC (HSBC), Caterpillar (CAT), BBVA (BBVA), Elevance Health (ELV), and Ecolab (ECL). The upgrades are based on price discounts to fair value estimates. The US market is moderately undervalued, trading at a 10% discount to fair value.
KFF reports 4.3 million Medicare beneficiaries will lose their plans by 2026, including 3.1 million MA-PD and 1.2 million PDP enrollees. CVS Health and Health Care Service Corp. lead PDP terminations. Centene reported PDP growth, while Humana, UnitedHealth, and CVS face MA-PD terminations. Average PDP choices drop to 9 in 2027 from 11 in 2026.
Wells Fargo raised its price target for Elevance Health (ELV) to $492, citing strong Medicaid and Exchanges performance. The firm increased its 2026 EPS estimate to $30.28, 4.5% above consensus. ELV reported Q3 earnings of $6.99 per share, beating estimates, and raised its full-year outlook. Other analysts also upgraded their price targets for the company.
Elevance Health Inc. shares fell 1.20% to $439.95 on Friday, underperforming the broader market. The stock is 2.38% below its 52-week high of $450.69, reached on October 21st.
